CRISPR Therapeutics AG CRSP
CRISPR Therapeutics AG (Nasdaq: CRSP) is a hematology drug developer. Its lead program, CASGEVY (exagamglogene autotemcel [exa-cel]), is in Phase 2 for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CASGEVY (exagamglogene autotemcel [exa-cel]) | sickle cell disease and transfusion-dependent beta thalassemia | gene therapy | Approved |
| CTX611 | total knee arthroplasty (anticoagulation) | RNA (siRNA/ASO/mRNA) | Phase 2 |
| zugocabtagene geleucel (zugo-cel) | relapsed or refractory B-cell malignancies (LBCL, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma) | cell therapy | Phase 2 |
| CTX310 | heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, severe hypertriglyceridemia | gene therapy | Phase 1 |
| CTX340 | refractory hypertension | gene therapy | Phase 1 |
| CTX460 | alpha-1 antitrypsin deficiency | gene therapy | Phase 1 |
| zugocabtagene geleucel (zugo-cel; CTX112) | systemic lupus erythematosus, systemic sclerosis, inflammatory myositis, immune thrombocytopenia purpura, warm autoimmune hemolytic anemia, progressive multiple sclerosis, neuromyelitis optica spectrum disorder, MOGAD, NMDAR, LGI1 autoimmune encephalitis, stiff person syndrome | cell therapy | Phase 1 |
| CTX321 | elevated Lp(a) | gene therapy | Pre-clinical |
| CTX213 | type 1 diabetes | cell therapy | Pre-clinical |
Recent results and decisions
- Nov 2, 2026approval CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT.
CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older.
Filing - Nov 2, 2026n/a FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C.
FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C.
Filing - Nov 2, 2026completed enrollment CRISPR Therapeutics completed enrollment in the Phase 2 clinical trial of CTX611 in patients undergoing total knee arthroplasty.
CRISPR Therapeutics has completed enrollment in the Phase 2 clinical trial of CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), in patients undergoing total knee arthroplasty (TKA), with an update expected in the second half of 2026.
Filing
8 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.